1. Generics Bulletin
  2. >>Business

Global Top Three Trade Places As Going Gets Tough, Especially In The US

 
• By Aidan Fry

Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.

123
The three leading generics, biosimilars and OTC players globally traded places last year as they focused more on boosting their bottom lines than striving for sales growth • Source: Shutterstock

At the end of July, Mylan’s management team is set hold an investors’ day at which it intends to spell out its plans to take the company forwards after a couple of fallow years financially. Difficulties in its home market, not least around manufacturing issues, led the US-headquartered company to report a 4% slip in group turnover last year.

Nevertheless, Mylan was able to claim top spot in the latest rankings of the world’s leading generics, biosimilars and OTC players compiled annually by Generics Bulletin, based on calculations from official sales disclosures made by companies. According to our calculations, Mylan’s turnover from generics, biosimilars and OTC products matched the group’s performance in slipping by 4%, falling to $10.017bn

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business